Related references
Note: Only part of the references are listed.EGFR Gene Status in Cytological Samples of Nonsmall Cell Lung Carcinoma Controversies and Opportunities
Gilda da Cunha Santos et al.
CANCER CYTOPATHOLOGY (2011)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Horwich et al.
ANNALS OF ONCOLOGY (2010)
Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
Amy J. Davidoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
Riichiroh Maruyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naive Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer
Noriyuki Ebi et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database
Taofeek K. Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
C. P. Belani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group trial (WJTOG 9904)
Shinzoh Kudoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
M Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers
DH Lee et al.
CLINICAL CANCER RESEARCH (2005)
Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from Surveillance, Epidemiology and End Results-Medicare
SA Ramsey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
C Gridelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Who gets chemotherapy for metastatic lung cancer?
CC Earle et al.
CHEST (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)